Status: Bibliographieeintrag
Standort: ---
Exemplare:
---
| |  Online-Ressource |
|---|
| Verfasst von: | AlWahsh, Mohammad [VerfasserIn]  |
|---|
| | Farhat, Joviana [VerfasserIn] |
|---|
| | Talhouni, Shahd [VerfasserIn] |
|---|
| | Hamadneh, Lama [VerfasserIn] |
|---|
| | Hergenröder, Roland [VerfasserIn] |
|---|
| Titel: | Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications |
|---|
| Titelzusatz: | review article |
|---|
| Verf.angabe: | Mohammad Alwahsh, Joviana Farhat, Shahd Talhouni, Lama Hamadneh, Roland Hergenröder |
|---|
| E-Jahr: | 2023 |
|---|
| Jahr: | January 16, 2023 |
|---|
| Umfang: | 23 S. |
|---|
| Fussnoten: | Gesehen am 03.06.2024 |
|---|
| Titel Quelle: | Enthalten in: EXCLI journal |
|---|
| Ort Quelle: | Dortmund : Leibniz Research Centre for Working Environment and Human Factors, 2002 |
|---|
| Jahr Quelle: | 2023 |
|---|
| Band/Heft Quelle: | 22(2023), Seite 146-168 |
|---|
| ISSN Quelle: | 1611-2156 |
|---|
| Abstract: | Bortezomib (BTZ) is a first-in-class reversible and selective proteasome inhibitor. It inhibits the ubiquitin proteasome pathway that leads to the degradation of many intracellular proteins. Initially, BTZ was FDA approved for the treatment of refractory or relapsed multiple myeloma (MM) in 2003. Later, its usage was approved for patients with previously untreated MM. In 2006, BTZ was approved for the treatment of relapsed or refractory Mantle Cell Lymphoma (MCL) and, in 2014, for previously untreated MCL. BTZ has been extensively studied either alone or in combination with other drugs for the treatment of different liquid tumors especially in MM. However, limited data evaluated the efficacy and safety of using BTZ in patients with solid tumors. In this review, we will discuss the advanced and novel mechanisms of action of BTZ documented in MM, solid tumors and liquid tumors. Moreover, we will shed the light on the newly discovered pharmacological effects of BTZ in other prevalent diseases. |
|---|
| DOI: | doi:10.17179/excli2022-5653 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.17179/excli2022-5653 |
|---|
| | kostenfrei: Volltext: https://www.excli.de/index.php/excli/article/view/5653 |
|---|
| | DOI: https://doi.org/10.17179/excli2022-5653 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | bortezomib |
|---|
| | liquid tumors |
|---|
| | multiple myeloma |
|---|
| | proteasome inhibitor |
|---|
| | solid tumors |
|---|
| K10plus-PPN: | 1890461571 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications / AlWahsh, Mohammad [VerfasserIn]; January 16, 2023 (Online-Ressource)
69219072
Zurück zur Trefferübersicht und Suche
